References

M
Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-29.
Mera J, Vellozzi C, Hariri S. Identification and clinical management of persons with chronic hepatitis C virus infection - Cherokee Nation, 2012-2015. MMWR Morb Mortal Wkly Rep. 2016;65(18):461-466. doi:10.15585/mmwr.mm6518a2.
Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2006;20(1):49-57.
Merck & Co. Inc. Zepatier Package insert. 2019.
Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2019;49(5):492-505. doi:10.1111/apt.15100.
Midgard H, Bjøro B, Mæland A, et al. Hepatitis C reinfection after sustained virological response. J Hepatol. 2016;64(5):1020-1026.
Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O. Hepatitis C treatment uptake among patients who have received opioid substitution treatment: a population-based study. PloS One. 2016;11(11):e0166451.
Miller L, Fluker SA, Osborn M, Liu X, Strawder A. Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc. 2012;104(5-6):244-250.
Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002;99(12):4588-4591.
Minton TD, Zeng Z. Bureau of Justice Statistics. Jail inmates in 2015. 2016.
Mira JA, Rivero-Juárez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56(11):1646-1653.
Mizuochi T, Takano T, Yanagi T, et al. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol. 2018;53:419-426.
Modi AA, Nazario H, Trotter JF, et al. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transpl. 2016;22(3):281-286.
Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet. 2016;55(5):605-613. doi: 10.1007/s40262-015-0334-7.
Mogalian E, Stamm LM, Osinusi A, et al. Drug-drug interaction studies between hepatitis C virus antivirals sofosbuvir/velpatasvir and boosted and unboosted human immunodeficiency virus antiretroviral regimens in healthy volunteers. Clin Infect Dis. 2018;56(6):934-940.
Molnar MZ, Nair S, Cseprekal O, et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience. Am J Transplant. 2019;19(11):3046-3057.
Molnar MZ, Azhar A, Tsujita M, et al. Transplantation of kidneys from hepatitis C virus-infected donors to hepatitis C virus-negative recipients: one-year kidney allograft outcomes. Am J Kidney Dis. 2021;77(5):739-747. doi:10.1053/j.ajkd.2020.10.017.
Moore BA, Barry DT, Sullivan LE, et al. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med. 2012;6(3):205-211.
Morey S, Hamoodi A, Jones D, Young T. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. J Viral Hepat. 2019;26(1):101-108.
Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833-844.
Top